total
kidney
transplant
perform
unit
state
incid
acut
reject
declin
probabl
graft
patient
surviv
continu
improv
usrd
infect
howev
remain
import
caus
morbid
mortal
kidney
transplant
estim
kidney
transplant
recipi
experi
infect
episod
within
first
year
transplant
dharnidharka
et
al
cardiovascular
diseas
infect
second
lead
caus
death
recipi
allograft
function
snyder
et
al
immunosuppress
therapi
requir
prevent
organ
reject
place
kidney
transplant
recipi
increas
risk
donorderiv
nosocomi
communityacquir
infect
well
reactiv
latent
pathogen
kidney
transplant
recipi
net
state
immun
suppress
epidemiolog
exposur
determin
risk
infect
given
time
tradit
timelin
use
predict
pattern
infect
organ
transplant
timelin
alter
recent
year
chang
immunosuppress
therapi
routin
use
antibacteri
antivir
prophylaxi
treatment
acut
reject
coinfect
virus
cytomegaloviru
cmv
epsteinbarr
viru
ebv
may
also
alter
predict
pattern
infect
fishman
basic
concept
tradit
timelin
howev
still
use
establish
differenti
diagnosi
infect
vari
interv
posttransplant
fig
within
first
month
infect
note
includ
relat
surgic
complic
nosocomi
exposur
donorderiv
pathogen
multidrugresist
organ
includ
methicillinresist
staphylococcu
aureu
mrsa
vancomycinresist
enterococcu
vre
carbapenemresist
enterobacteriacea
cre
import
consider
clostridium
difficil
urinari
tract
infect
common
within
first
month
opportunist
infect
like
occur
month
transplant
reflect
greater
impact
immun
suppress
time
reactiv
latent
pathogen
polyoma
viru
bk
hepat
c
viru
hcv
mycobacterium
tuberculosi
may
also
occur
prophylaxi
pneumocysti
jiroveci
herp
virus
includ
cmv
hepat
b
viru
hbv
make
infect
less
common
time
period
beyond
month
degre
immun
suppress
patient
decreas
risk
remain
howev
communityacquir
infect
environment
exposur
recurr
infect
late
present
viral
infect
particular
cmv
prophylaxi
discontinu
fishman
karuthu
blumberg
intervent
undertaken
reduc
impact
infect
kidney
transplant
pretranspl
screen
donor
recipi
infect
transmit
organ
donat
reactiv
immun
suppress
recipi
essenti
optim
transplant
outcom
guidelin
pretranspl
screen
avail
american
societi
transplant
fischer
et
al
kidney
diseas
improv
global
outcom
kdigo
us
public
health
servic
seem
et
al
recommend
screen
test
donor
recipi
list
tabl
screen
live
donor
perform
prior
transplant
vari
time
signific
delay
day
screen
time
transplant
live
donor
reevalu
ruleout
recent
acquir
infect
cdc
recommend
live
donor
rescreen
human
immunodefici
viru
hiv
prior
donat
exclud
recent
infect
cdc
repeat
screen
hcv
hbv
may
also
indic
risk
factor
infect
identifi
fischer
et
al
deceas
donor
screen
contrast
time
constraint
usual
perform
within
hour
transplant
coordin
organ
procur
organ
infect
hiv
hbv
hcv
may
detect
earli
stage
infect
mani
transplant
center
perform
sensit
rapid
molecular
test
potenti
organ
donor
includ
nucleic
acid
amplif
nat
test
hiv
hbv
hcv
comprehens
medic
social
histori
potenti
organ
donor
requir
order
identifi
risk
factor
blood
born
pathogen
effort
expand
pool
avail
organ
recipi
may
consent
receipt
kidney
nat
neg
donor
deem
high
risk
blood
born
infect
base
identifi
risk
factor
recipi
organ
monitor
posttransplant
test
hiv
hbv
hcv
month
hbv
month
fischer
et
al
seem
et
al
kovac
et
al
len
et
al
use
hcv
hbvposit
organ
consid
respect
posit
recipi
furthermor
hiv
organ
polici
equiti
act
lift
longstand
ban
allow
hivposit
organ
donat
hivposit
recipi
mgbako
et
al
muller
et
al
donor
activ
bacteri
infect
time
kidney
procur
may
transmit
infect
recipi
screen
bacteri
infect
kidney
donor
includ
assess
urinari
tract
infect
bacteremia
urin
blood
cultur
data
review
kidney
donor
known
urinari
tract
system
infect
virul
organ
staphylococcu
aureu
pseudomona
aeruginosa
candida
speci
organ
recipi
usual
treat
day
cours
target
antimicrobi
therapi
sinc
bacteria
compromis
vascular
urinari
anastomos
lead
mycot
aneurysm
anastomot
organ
failur
fischer
et
al
allograft
contamin
occur
organ
procur
process
interpret
organ
preserv
fluid
cultur
challeng
risk
transmiss
infect
organ
recipi
contamin
preserv
fluid
howev
low
fischer
et
al
len
et
al
candid
kidney
transplant
vaccin
statu
review
updat
accord
recommend
issu
advisori
committe
immun
practic
center
diseas
control
prevent
cdc
vaccin
end
stage
renal
diseas
patient
may
less
effect
durabl
healthi
patient
better
respons
anticip
prior
transplant
janu
et
al
kausz
pahari
special
consider
given
vaccin
pneumococcu
influenza
hbv
two
pneumococc
vaccin
current
licens
use
unit
state
pneumococc
conjug
vaccin
pcv
prevnar
vaccin
ppsv
pneumovax
current
guidelin
recommend
unvaccin
patient
chronic
renal
failur
receiv
pcv
follow
least
week
later
ppsv
kobayashi
et
al
second
dose
ppsv
recommend
year
first
dose
cdc
influenza
vaccin
administ
annual
number
influenza
vaccin
formul
avail
live
attenu
influenza
vaccin
flumist
recommend
chronic
kidney
diseas
patient
inactiv
vaccin
option
use
cdc
high
dose
inactiv
influenza
vaccin
avail
shown
induc
higher
antibodi
respons
tradit
vaccin
adult
age
diazgranado
et
al
use
vaccin
transplant
candid
recipi
current
investig
transplant
candid
immun
hbv
receiv
high
dose
hbv
vaccin
microgram
antigen
per
dose
due
decreas
respons
rate
standard
dose
huprikar
et
al
human
cytomegaloviru
human
herp
cmv
member
famili
herpesvirida
opportunist
pathogen
occur
solid
organ
transplant
recipi
brennan
cmv
caus
signific
morbid
mortal
popul
mwintshi
brennan
incid
cmv
renal
transplant
popul
estim
patel
paya
renal
transplant
patient
lower
risk
primari
cmv
compar
organ
transplant
recipi
owe
lower
burden
latent
viru
renal
allograft
tissu
risk
factor
develop
cmv
diseas
includ
donor
seropositivityrecipi
seroneg
use
induct
immunosuppress
antilymphocyt
antibodi
donor
age
year
simultan
kidneypancrea
transplant
treatment
acut
reject
impair
transplant
function
concurr
infect
virus
like
ebv
de
keyzer
et
al
cmvseroneg
recipi
cmvseroposit
donor
highest
risk
wherea
dr
transplant
consid
moder
risk
lowest
risk
incid
cmv
diseas
de
keyzer
et
al
immunosuppress
drug
also
influenc
incid
sever
cmv
diseas
instanc
cyclosporin
increas
risk
cmv
diseas
wherea
use
sirolimu
seem
protect
effect
san
juan
et
al
use
antilymphocyt
antibodi
antithymocyt
globulin
associ
two
fivefold
increas
rate
cmv
basiliximab
daclizumab
seem
increas
incid
de
keyzer
et
al
cmv
infect
may
occur
solid
organ
transplant
recipi
primari
infect
cmv
seroneg
individu
receiv
cell
latent
infect
cmv
seroposit
donor
donorderiv
reinfect
reactiv
latent
recipi
infect
patel
paya
follow
definit
commonli
use
transplant
literatur
differenti
cmv
infect
cmv
diseas
cmv
infect
evid
cmv
replic
regardless
symptom
cmv
diseas
evid
cmv
infect
symptom
viral
syndrom
leukopenia
thrombocytopenia
invas
tissu
diseas
eg
pneumon
hepat
retin
gastrointestin
diseas
humar
snydman
cmv
diseas
even
asymptomat
cmv
infect
shown
independ
risk
factor
reduc
graft
surviv
overal
mortal
beyond
day
posttransplant
saged
et
al
infect
cmv
implic
acut
allograft
dysfunct
chronic
allograft
nephropathi
mclaughlin
et
al
tong
et
al
cmv
diseas
also
associ
posttranspl
lymphoprolif
disord
ptld
posttranspl
diabet
mellitu
transplant
arteri
stenosi
pouria
et
al
hjelmesaeth
et
al
manez
et
al
cmv
infect
occur
acut
infect
first
month
follow
transplant
immunosuppress
maximum
delay
infect
reactiv
latent
viru
antivir
prophylaxi
complet
later
first
year
given
signific
effect
cmv
patient
outcom
prevent
play
import
role
serolog
screen
cmv
perform
donor
recipi
prior
transplant
categor
high
risk
patient
sever
cmv
vaccin
candid
investig
although
none
current
avail
univers
prophylaxi
involv
give
antivir
recipi
risk
posttranspl
onset
infect
wherea
preemptiv
therapi
patient
monitor
regular
interv
start
antivir
earli
evid
replic
prior
onset
clinic
diseas
chemoprophylaxi
high
risk
patient
shown
reduc
incid
cmv
diseas
decreas
cmv
associ
mortal
opportunist
infect
hodson
et
al
preemptiv
therapi
high
risk
patient
base
cmv
viral
load
monitor
shown
reduct
acut
reject
allcaus
mortal
strippoli
et
al
random
control
trial
kliem
et
al
compar
oral
ganciclovir
chemoprophylaxi
viral
load
monitor
reveal
improv
graft
surviv
receiv
ganciclovir
chemoprophylaxi
kliem
et
al
recent
cochran
review
conclud
efficaci
preemptiv
therapi
compar
prophylaxi
prevent
cmv
diseas
remain
unclear
due
signific
heterogen
studi
addit
headtohead
studi
requir
determin
rel
benefit
harm
preemptiv
therapi
prophylaxi
prevent
cmv
diseas
solid
organ
transplant
recipi
ower
et
al
standard
prophylact
guidelin
recommend
therapi
dr
use
oral
ganciclovir
valganciclovir
minimum
month
posttranspl
month
treatment
reject
antilymphocyt
therapi
humar
snydman
kotton
et
al
valganciclovir
replac
ganciclovir
better
bioavail
lower
pill
burden
reduc
avail
oral
ganciclovir
paya
et
al
optim
length
prophylaxi
unknown
recent
trial
shown
month
prophylaxi
effect
decreas
incid
cmv
diseas
kidney
transplant
recipi
humar
et
al
doyl
et
al
current
guidelin
recommend
dose
valganciclovir
mg
daili
adjust
renal
dysfunct
toler
recipi
center
success
treat
patient
half
dose
mg
daili
less
drug
toxic
howev
recipi
may
higher
risk
breakthrough
infect
develop
resist
lower
dose
strategi
kotton
et
al
diagnosi
cmv
diseas
made
sever
techniqu
includ
cmv
antigenemia
assay
nucleic
acid
test
nat
serolog
antibodi
test
viral
cultur
histopatholog
nat
gener
sensit
antibodi
test
cultur
higher
valu
nat
suggest
cmv
diseas
weekli
viremia
test
use
monitor
respons
therapi
interlaboratori
variabl
nat
expect
reduc
recent
establish
intern
standard
intend
use
standard
nucleic
acid
amplif
techniqu
nat
base
assay
hcmv
karuthu
blumberg
patient
gastrointestin
neurolog
cmv
diseas
often
fail
exhibit
cmv
viremia
histopatholog
necessari
establish
diagnosi
instanc
treatment
activ
cmv
diseas
requir
combin
immunomodul
antivir
therapi
without
adjuv
therapi
possibl
reduct
immunosuppress
kotton
et
al
green
et
al
mainstay
therapi
intraven
ganciclovir
victor
trial
valcyt
cmv
diseas
treatment
solid
organ
recipi
demonstr
oral
valganciclovir
inferior
intraven
ganciclovir
mild
moder
cmv
diseas
solid
organ
transplant
recipi
asberg
et
al
current
guidelin
recommend
renal
adjust
intraven
ganciclovir
mgkg
twice
daili
oral
valganciclovir
mg
twice
daili
mild
cmv
diseas
kotton
et
al
sever
cmv
diseas
intraven
ganciclovir
prefer
reduct
immunosupress
despit
increas
risk
reject
de
keyzer
et
al
use
adjuv
therapi
cmvspecif
hyperimmun
globulin
standard
intraven
immunoglobulin
may
consid
individu
hypogammaglobulinemia
sever
system
infect
failur
respond
standard
therapi
humar
et
al
cmv
resist
ganciclovir
note
renal
transplant
recipi
due
mutat
ul
gene
respons
first
phosphoryl
step
ganciclovir
activ
ul
gene
respons
dna
polymeras
limay
et
al
cmv
resist
consid
patient
worsen
diseas
persist
unchang
viremia
week
therapi
case
genotyp
test
mutat
gene
encod
ul
ul
perform
weikert
blumberg
treatment
option
drug
resist
cmv
includ
use
high
dose
ganciclovir
foscarnet
cidofovir
howev
clinic
trial
data
avail
regard
optim
therapi
option
resist
cmv
use
novel
agent
includ
leflunomid
artesun
attempt
salvag
therapi
vari
success
sever
new
antivir
treatment
option
current
investig
includ
maribavir
brincidofovir
oral
prodrug
cidofovir
less
nephrotox
use
treatment
drug
resist
cmv
limay
et
al
epstein
barr
viru
human
herpesviru
ebv
ubiquit
gamma
herp
viru
remain
latent
lymphocyt
follow
primari
infect
respons
posttranspl
lymphoprolif
disord
ptld
increas
morbid
mortal
transplant
popul
approxim
ptld
case
associ
ebv
karuthu
blumberg
ptld
commonli
occur
first
year
posttranspl
cockfield
et
al
risk
factor
ptld
includ
ebv
recipi
receiv
ebv
seroposit
organ
activ
primari
ebv
infect
younger
recipi
coinfect
cmv
virus
prior
splenectomi
second
transplant
acut
chronic
graft
versu
host
diseas
immunosuppress
drug
regimen
polyclon
antilymphocyt
antibodi
type
organ
transplant
kidney
transplant
recipi
lower
risk
compar
type
transplant
incid
approxim
gulley
tang
allen
et
al
taylor
et
al
major
symptomat
ebv
infect
renal
transplant
recipi
primari
infect
like
relat
transmiss
donor
viru
ebv
diseas
asymptomat
present
nonspecif
febril
syndrom
lymphadenopathi
hepatosplenomegali
atyp
lymphocytosi
hematolog
disord
includ
anemia
leukopenia
thrombocytopenia
organspecif
diseas
like
gastroenter
hepat
pneumon
allen
et
al
ptld
typic
follow
primari
infect
frequent
present
rapidli
enlarg
mass
graft
organ
lymph
node
bone
marrow
extranod
site
manez
et
al
ptld
divid
four
major
histopatholog
subtyp
per
world
health
organ
earli
lesion
polymorph
ptld
monomorph
ptld
classic
hodgkin
lymphoma
type
ptld
definit
diagnosi
ptld
requir
histopatholog
confirm
tissu
excis
biopsi
immunolog
cell
type
cytogenet
immunoglobulin
gene
rearrang
ebvspecif
stain
allen
et
al
stage
perform
histolog
type
monoclon
versu
polyclon
cell
versu
b
cell
locat
allograft
organ
metastasi
weikert
blumberg
clinic
manag
ptld
typic
involv
reduct
immunosuppress
lead
remiss
patient
weikert
blumberg
antivir
therapi
acyclovir
ganciclovir
controversi
evid
support
efficaci
taylor
et
al
rituximab
monoclon
antibodi
commonli
use
treatment
ptld
recipi
fail
reduct
immunosuppress
alon
allen
et
al
isol
graft
ptld
surgic
resect
option
weikert
blumberg
patient
fail
strategi
ifn
ivig
use
vari
success
cytotox
chemotherapi
radiat
remain
salvag
therapi
green
et
al
standard
therapi
prevent
ptld
kdigo
guidelin
recommend
monitor
ebv
viral
load
high
risk
renal
transplant
patient
within
first
week
transplant
least
monthli
month
everi
month
rest
first
posttranspl
year
addit
viral
load
monitor
recommend
treatment
acut
reject
high
risk
group
children
ebv
outcom
ptld
renal
transplant
patient
vari
accord
site
involv
patient
isol
graft
involv
surviv
compar
patient
ptld
extend
beyond
allograft
whose
surviv
vari
weikert
blumberg
human
herpesviru
herp
simplex
viru
type
hsv
human
herpesviru
varicella
zoster
viru
vzv
alpha
herp
virus
hsv
seropreval
adult
popul
hsv
seropreval
vzv
rate
high
green
et
al
incid
hsv
diseas
renal
transplant
recipi
approxim
vzv
patel
paya
hsv
may
caus
primari
infect
follow
viru
remain
latent
sensori
nerv
ganglia
commonli
caus
reactiv
infect
hsv
may
seen
earli
first
posttranspl
month
absenc
prophylaxi
hsv
infect
usual
present
oral
genit
mucocutan
lesion
occasion
pneumon
tracheobronch
esophag
hepat
enceph
dissemin
infect
green
et
al
vzv
caus
local
dermatom
multidermatom
dissemin
zoster
without
viscer
involv
pneumon
hepat
pancreat
enceph
pretranspl
screen
prior
vzv
infect
perform
patient
vaccin
live
attenu
varicella
vaccin
transplant
whenev
possibl
order
avoid
primari
vzv
infect
posttransplant
fehr
et
al
sinc
vzv
live
vaccin
given
transplant
expect
within
week
order
avoid
activ
shed
viru
time
transplant
posttranspl
prophylaxi
recommend
acyclovir
valacyclovir
ganciclovir
need
cmv
prophylaxi
approxim
month
posttranspl
order
avoid
hsv
vzv
reactiv
green
et
al
diagnosi
hsv
vzv
infect
made
pcr
direct
fluoresc
antibodi
hsv
vesicular
lesion
csf
viscer
tissu
sampl
serolog
rare
help
activ
infect
owe
high
seropreval
kdigo
guidelin
recommend
renal
transplant
recipi
develop
less
sever
hsv
vzv
infect
treat
appropri
oral
antivir
agent
eg
acyclovir
valacyclovir
famciclovir
system
infect
treat
intraven
acyclovir
reduct
immunosuppress
medic
subsequ
switch
appropri
oral
antivir
agent
green
et
al
use
foscarnet
cidofovir
topic
trifluridin
may
consid
patient
acyclovir
resist
viru
care
monitor
renal
function
kotton
fishman
tan
goh
human
herpesviru
human
herpesviru
hhv
hhv
ubiquit
high
seropreval
adult
virus
common
caus
fever
children
remain
latent
lymphocyt
follow
primari
infect
hhv
use
molecul
receptor
may
also
infect
cell
type
monocyt
epitheli
endotheli
cell
hhv
use
molecul
receptor
strictli
lymphotrop
infect
occur
result
reactiv
first
week
follow
transplant
often
recipi
cmv
prophylaxi
singh
carrigan
clinic
manifest
includ
fever
rash
hepat
interstiti
pneumon
enceph
leukopenia
myelosuppress
owe
immunomodulatori
effect
hypothes
hhv
may
act
cofactor
hhv
cmv
reactiv
hhv
hhv
may
act
cofactor
pathogenesi
cmv
diseas
acut
reject
kidd
et
al
chapenko
et
al
dockel
paya
diagnosi
hhv
hhv
made
tissu
immunohistochemistri
nat
test
peripher
blood
lymphocyt
treatment
includ
reduct
immunosuppress
ganciclovir
cidofovir
foscarnet
also
util
green
et
al
kotton
fishman
dockel
paya
hhv
associ
primari
effus
lymphoma
kaposi
sarcoma
multicentr
castleman
diseas
infect
acquir
primari
allograft
reactiv
latent
viru
diociaiuti
et
al
regami
et
al
hhv
caus
kaposi
sarcoma
common
present
renal
transplant
recipi
upregul
vascular
endotheli
growth
factor
vegf
receptor
endotheli
cell
stallon
et
al
treatment
includ
reduct
immunosuppress
cytotox
chemotherapi
sirolimu
immunosuppress
drug
use
renal
transplant
patient
thought
inhibit
product
vegf
also
dampen
effect
endotheli
cell
stallon
et
al
bk
polyomaviru
bkv
jc
polyomaviru
jcv
belong
famili
polyomavirida
bkv
respons
caus
polyomaviru
associ
nephropathi
pvan
case
jcv
less
case
pvan
occur
patient
renal
transplant
caus
renal
allograft
loss
case
drachenberg
et
al
dadhania
et
al
risk
factor
bkv
associ
pvan
includ
use
potent
immunosuppress
regimen
caucasian
race
older
age
diabet
mellitu
cadaver
renal
transplant
combin
kidney
pancrea
transplant
hirsch
et
al
trofe
et
al
bkv
known
caus
interstiti
nephriti
ureter
stenosi
ureter
strictur
allograft
kidney
commonli
occur
within
first
month
renal
transplant
patient
immunosuppress
highest
randhawa
brennan
jcv
less
commonli
caus
pvan
frequent
associ
progress
multifoc
leukoencephalopathi
pml
demyelin
disord
white
matter
present
neurolog
impair
dementia
phillip
et
al
diagnosi
bkv
includ
use
viral
load
assay
blood
urin
detect
viral
cytopath
effect
decoy
cell
nat
bkvspecif
antibodi
histopatholog
hariharan
kdigo
guidelin
recommend
screen
renal
transplant
recipi
bkv
quantit
plasma
nat
least
monthli
first
month
transplant
everi
month
end
first
posttranspl
year
whenev
unexplain
rise
serum
creatinin
treatment
acut
reject
guidelin
suggest
reduc
immunosuppress
medic
bkv
plasma
nat
persist
greater
copiesml
copiesl
kdigo
sustain
high
bk
viremia
spite
reduct
immunosuppress
may
need
addit
antivir
therapi
although
data
regard
optim
treatment
option
unknown
limit
data
regard
effect
leflunomid
andor
cidofovir
use
fluoroquinolon
ivig
treatment
bkv
infect
randhawa
brennan
josephson
et
al
date
effect
treatment
pml
patient
allograft
loss
due
pvan
undergon
success
retransplant
hariharan
patient
chronic
renal
failur
particular
receiv
hemodialysi
increas
risk
contract
hepat
b
viru
hbv
preval
hepat
b
surfac
antigen
hbsag
posit
patient
declin
hbv
vaccin
strict
segreg
hbsagposit
patient
dialysi
unit
improv
screen
blood
product
use
erythropoiesi
stimul
agent
karuthu
blumberg
approxim
patient
histori
hbv
prior
transplant
reactiv
posttranspl
weikert
blumberg
serial
monitor
hbv
dna
everi
month
requir
transplant
liver
enzym
level
reflect
infect
statu
elev
viral
load
suggest
resist
therapi
levitski
et
al
metaanalysi
conduct
fabrizi
colleagu
hbsag
seroposit
independ
risk
factor
allograft
loss
posttranspl
death
fabrizi
et
al
treatment
option
current
approv
chronic
hbv
includ
ifn
alpha
pegyl
ifn
lamivudin
entecavir
telbivudin
tenofovir
adefovir
fabrizi
et
al
chan
et
al
chang
et
al
kdigo
recommend
interferon
treatment
gener
avoid
high
associ
incid
reject
tenofovir
entecavir
prefer
lamivudin
minim
develop
drug
resist
unless
medic
cost
requir
lamivudin
use
therapi
antivir
hbv
dna
alt
level
measur
everi
month
monitor
efficaci
detect
drug
resist
hbsagposit
renal
transplant
recipi
receiv
prophylaxi
tenofovir
entecavir
lamivudin
hbsagposit
patient
cirrhosi
screen
hepatocellular
carcinoma
everi
month
liver
ultrasound
alpha
fetoprotein
patient
neg
hbsag
hbsab
titer
miuml
receiv
booster
vaccin
rais
titer
miuml
kdigo
hepat
c
viru
hcv
infect
increasingli
recogn
end
stage
renal
diseas
patient
esrd
donorderiv
hcv
may
uncommonli
occur
transplant
screen
patient
esrd
test
renal
transplant
patient
newli
acquir
hcv
includ
nat
levitski
et
al
hcvposit
donor
consid
hcvposit
recipi
possibl
consid
hcvneg
recipi
futur
given
improv
treatment
option
cure
hcv
could
administ
post
transplant
hcvinfect
renal
transplant
recipi
decreas
surviv
increas
complic
rate
posttranspl
complic
includ
glomerulonephr
gn
posttranspl
diabet
mellitu
acceler
progress
cirrhosi
fibros
cholestat
hepat
moral
et
al
liver
biopsi
within
month
transplant
subsequ
biopsi
requir
evalu
liver
diseas
posttranspl
patient
may
normal
liver
enzym
level
abnorm
histolog
featur
ashri
ahm
gheith
hcvinfect
recipi
test
proteinuria
everi
month
patient
new
onset
proteinuria
undergo
allograft
biopsi
kdigo
effect
immunosuppress
progress
hcvrelat
liver
injuri
manag
immunosuppress
hcvinfect
renal
transplant
recipi
remain
uncertain
thu
prefer
treat
hcv
transplant
candid
prior
transplant
given
potenti
improv
outcom
success
hcv
treatment
complic
associ
treatment
posttranspl
patient
sustain
virolog
respons
pretranspl
treatment
reduc
risk
hcv
recurr
decreas
posttranspl
gn
moral
option
treatment
includ
interferonpeginterferon
alon
combin
ribavirin
risk
toxic
addit
ribavirin
limit
use
combin
therapi
chronic
kidney
diseas
ckd
patient
avail
direct
act
hcv
proteas
polymeras
inhibitor
spark
new
enthusiasm
treat
hcvinfect
ckd
patient
studi
ongo
evalu
use
agent
ckd
treatment
given
prior
transplant
kdigo
recommend
monotherapi
standard
interferon
hcvinfect
renal
transplant
recipi
benefit
antivir
treatment
clearli
outweigh
risk
kdigo
use
direct
act
hcv
antivir
posttransplant
also
consid
like
prefer
futur
given
improv
toler
efficaci
agent
understand
drug
interact
calcineurin
inhibitor
may
occura
studi
look
hcvposit
kidney
transplant
recipi
treat
pretranspl
interferon
unsuccess
treat
direct
act
antivir
posttranspl
found
clear
viru
sustain
virolog
respons
week
common
agent
use
sofosbuvir
simeprevir
sawinski
et
al
human
immunodefici
viru
hiv
belong
famili
retrovirida
introduct
antiretrovir
therapi
art
incid
hiv
relat
death
reduc
renal
diseas
relat
hiv
infect
includ
hiv
associ
nephropathi
hivan
immun
complex
diseas
thrombot
microangiopathi
frassetto
et
al
total
patient
hiv
develop
hivan
remain
import
complic
hiv
infect
progress
rapidli
end
stage
renal
diseas
esrd
shahinian
et
al
larg
prospect
clinic
trial
examin
outcom
among
hiv
kidney
transplant
recipi
report
patient
graft
surviv
rate
respect
similar
surviv
rate
among
cohort
unmatch
elderli
year
hivneg
kidney
recipi
stock
et
al
candid
transplant
includ
wellcontrol
hiv
infect
undetect
viral
load
cell
per
microlit
absenc
untreat
infect
malign
blumberg
et
al
signific
complic
patient
popul
posttranspl
includ
increas
reject
rate
manag
drug
interact
art
immunosuppress
therapi
complic
relat
cardiovascular
risk
factor
hepat
coinfect
blumberg
et
al
choic
art
base
suscept
result
possibl
use
proteas
inhibitor
avoid
owe
signific
drug
interact
class
art
regard
immunosuppress
therapi
use
thymoglobulin
may
result
prolong
depress
count
wherea
monoclonc
receptor
antibodi
basiliximabdaclizumab
shown
increas
cell
count
ciuffreda
et
al
carter
et
al
risk
antilymphocyt
therapi
balanc
risk
reject
hivinfect
recipi
note
hivposit
donor
consid
hivposit
recipi
variou
respiratori
viru
es
caus
infect
affect
renal
transplant
patient
popul
includ
adenoviru
respiratori
syncyti
viru
rsv
influenza
parainfluenza
human
metapneumoviru
rhinoviru
coronaviru
green
et
al
clinic
manifest
includ
upper
respiratori
tract
infect
bronchiti
pneumonia
addit
respiratori
ill
adenoviru
known
caus
gastroenter
hemorrhag
cystiti
pancreat
meningoenceph
necrot
hepat
nephritisren
dysfunct
renal
transplant
recipi
pham
et
al
alsaad
et
al
infect
virus
may
also
associ
reject
weikert
blumberg
prevent
involv
hand
hygien
use
droplet
precaut
suspect
infect
influenza
vaccin
recommend
prior
transplant
yearli
follow
transplant
treatment
respiratori
viral
infect
involv
support
care
antivir
medic
influenza
treat
oseltamivir
zanamavir
ribavirin
approv
treatment
rsv
adenoviru
infect
treat
reduct
immunosuppress
consider
cidofovir
ison
emerg
viral
pathogen
includ
newli
recogn
virus
previous
known
virus
either
increas
threaten
increas
incid
emerg
virus
caus
infect
renal
transplant
popul
includ
human
tcell
leukemia
viru
type
hepat
e
viru
hev
measl
viru
rabi
viru
lymphocyt
choriomening
viru
lcmv
dengu
viru
denv
west
nile
viru
zika
viru
case
report
adult
tcell
leukemia
atl
follow
renal
transplant
patient
document
though
case
seri
renal
transplant
recipi
longterm
followup
case
atl
myelopathi
ham
develop
nakamura
et
al
tanab
et
al
hev
may
induc
kidney
injuri
signific
reduct
glomerular
filtrat
rate
glomerular
injuri
membranoprolif
glomerulonephr
describ
kidney
transplant
patient
acut
chronic
hev
infect
kamar
et
al
incid
measl
transplant
recipi
unclear
case
subacut
measl
enceph
sme
develop
renal
transplant
recipi
clinic
cours
one
deterior
mental
statu
treatment
refractori
seizur
waggon
deresinski
worldwid
vectorborn
viral
diseas
increas
incid
transmit
blood
product
organ
transplant
fatal
case
dengu
report
within
first
month
follow
renal
transplant
waggon
deresinski
west
nile
viru
also
report
transplant
recipi
high
incid
neuroinvas
diseas
poor
outcom
zika
viru
also
concern
case
donorderiv
rabi
sot
popul
report
patient
typic
develop
enceph
month
posttranspl
symptomat
report
patient
die
srinivasan
et
al
case
lcmv
caus
sever
diseas
organ
transplant
patient
document
cluster
lcmv
infect
occur
unit
state
involv
kidney
liver
lung
transplant
symptom
includ
fever
abdomin
pain
nausea
diarrhea
alter
mental
statu
srinivasan
et
al
barri
et
al
fischer
et
al
two
renal
transplant
recipi
surviv
lcmv
infect
ribavirin
employ
case
though
benefit
remain
unclear
waggon
deresinski
data
regard
incid
screen
treatment
option
abovement
emerg
virus
limit
given
risk
donorderiv
viral
transmiss
organ
accept
donor
unexplain
febril
neurolog
ill
unclear
case
risk
donorderiv
infect
balanc
benefit
transplant
risk
factor
urinari
tract
infect
transplant
prolong
period
hemodialysi
transplant
prolong
bladder
catheter
femal
sex
deceas
donor
transplant
kidneypancrea
transplant
bladder
drainag
ureteroves
stent
increas
immunosuppress
state
karuthu
blumberg
lapchik
et
al
prophylaxi
lower
risk
infect
transplant
trimethoprimsulfamethoxazol
routin
karuthu
blumberg
controversi
regard
exact
dose
durat
prophylaxi
exist
typic
given
dose
mg
trimethoprim
mg
sulfamethoxazol
daili
month
kdigo
trimethoprimsulfamethoxazol
reduc
risk
uti
bacteremia
karuthu
blumberg
patel
paya
symptom
uti
includ
frequenc
urgenc
dysuria
well
nausea
vagu
abdomin
complaint
patient
asymptomat
escherichia
coli
common
pathogen
increas
number
pathogen
multidrug
resist
sensit
test
requir
treatment
asymptomat
bacteriuria
renal
transplant
recipi
controversi
routin
recommend
coussement
abramowicz
although
well
studi
sinc
uti
renal
transplant
patient
complic
day
antibiot
typic
durat
remov
stent
cathet
well
drainag
abscess
frequent
requir
prevent
relaps
cure
surgic
wound
infect
occur
rate
usual
present
within
first
week
transplant
ramo
et
al
obes
urin
leak
reoper
origin
incis
diabet
high
creatinin
level
plasma
prolong
bladder
catheter
risk
factor
wound
infect
humar
et
al
khouri
brennan
improv
organ
procur
preserv
surgic
techniqu
along
preoper
antibiot
reduc
risk
subsequ
postop
wound
infect
bacteri
organ
caus
type
infect
may
nosocomi
multidrugresist
make
antibiot
treatment
difficult
due
limit
option
toxic
sourc
control
good
wound
care
critic
manag
type
infect
although
pneumonia
common
bacteri
infect
solid
organ
transplant
recipi
incid
lowest
receiv
kidney
khouri
brennan
occur
earli
posttranspl
period
cmv
infect
reject
treatment
antilymphocyt
prepar
increas
pneumonia
risk
hospitalacquir
pneumonia
due
resist
pathogen
mrsa
extend
spectrum
beta
lactamas
esbl
carbapenemresist
cre
gramneg
organ
increas
incid
sometim
requir
nephrotox
agent
treatment
communityacquir
pneumonia
occur
time
transplant
incid
communityacquir
pneumonia
specif
due
streptococcu
pneumonia
lower
vaccin
bacteremia
sepsi
commonli
due
urinari
sourc
follow
lung
wound
abdomen
khouri
brennan
intraven
cathet
also
play
role
diabet
mellitu
posttranspl
dialysi
increas
incid
sepsi
decreas
surviv
rate
patient
abbott
et
al
prompt
treatment
broad
spectrum
antibiot
follow
rapid
deescal
pathogenspecif
therapi
base
sensit
requir
remov
foreign
bodi
intraven
cathet
stent
also
necessari
cure
nocardia
rare
infect
seen
renal
transplant
recipi
occur
less
patient
wilson
et
al
trimethoprimsulfamethoxazol
prophylaxi
use
transplant
prevent
pneumocysti
jiroveci
pneumonia
pcp
like
prevent
nocardia
infect
well
nocardia
asteroid
common
speci
caus
pulmonari
infect
includ
cavitari
lesion
pleural
effus
patel
paya
common
site
infect
due
dissemin
central
nervou
system
cn
cutan
patient
nocardia
evalu
cn
diseas
allograft
reject
highdos
prednison
azathioprin
instead
cyclosporin
base
immunosuppress
neutropenia
risk
factor
infect
patel
paya
diagnosi
made
identif
branch
bead
rod
gram
modifi
acid
fast
stain
cultur
infect
site
antimicrobi
suscept
test
perform
isol
high
dose
trimethoprimsulfamethoxazol
sometim
combin
amikacin
treatment
choic
allerg
reaction
side
effect
sometim
limit
use
altern
includ
imipenem
minocyclin
ceftriaxon
choic
base
suscept
site
infect
spelman
nocardia
infect
relaps
prolong
therapi
year
recommend
follow
chronic
suppress
therapi
spelman
arduino
et
al
listeria
monocytogen
bacteri
organ
transmit
commonli
summer
earli
fall
human
via
gastrointestin
tract
contamin
dairi
product
raw
veget
meat
although
common
first
month
transplant
infect
may
occur
point
risk
increas
reject
therapi
patel
paya
infect
involv
central
nervou
system
mening
meningoenceph
common
present
headach
fever
meningismu
alter
mental
statu
possibl
focal
neurolog
deficit
includ
cranial
nerv
palsi
seizur
patel
paya
cerebrospin
fluid
examin
typic
reveal
pleocytosi
mostli
polymorphonuclear
leukocyt
decreas
glucos
elev
protein
name
impli
mononuclear
predomin
may
occur
instead
gram
stain
low
sensit
may
neg
reveal
gram
posit
bacilli
may
confus
diphtheroid
site
infect
includ
bacteremia
pneumonia
endophthalm
septic
arthriti
trimethoprimsulfamethoxazol
use
p
carinii
prophylaxi
may
also
prevent
infect
listeria
treatment
choic
intraven
ampicillin
gentamicin
week
cn
infect
prevent
relaps
gentamicin
usual
continu
shorter
durat
week
kidney
function
stabl
gelfand
trimethoprimsulfamethoxazol
altern
treatment
allerg
penicillin
decreas
immunosuppress
agent
sometim
alway
necessari
immunosuppress
increas
risk
develop
mycobacterium
tuberculosi
tb
diseas
although
major
tuberculosi
infect
renal
transplant
recipi
occur
first
month
tb
occur
time
transplant
khouri
brennan
overal
incid
lower
unit
state
compar
rest
world
foreignborn
recipi
greatest
risk
high
index
suspicion
import
renal
transplant
patient
present
atyp
pretranspl
screen
tuberculin
skin
test
ifngamma
releas
assay
unreli
chronic
kidney
diseas
patient
due
anergi
extrapulmonari
site
infect
dissemin
diseas
occur
third
case
karuthu
blumberg
laryng
mening
skelet
cutan
intestin
renal
infect
exampl
extrapulmonari
diseas
fever
common
sweat
weight
loss
may
absent
patel
paya
screen
prior
transplant
includ
histori
regard
prior
exposur
treatment
tb
well
chest
xray
urin
afb
cultur
prophylaxi
isoniazid
rifampin
offer
patient
prior
transplant
histori
inadequ
treat
tb
abnorm
chest
xray
suggest
prior
tb
exposur
posit
ppd
ifn
gamma
assay
contact
someon
activ
tb
kidney
ppdposit
donor
order
minim
reactiv
diseas
transplant
khouri
brennan
patient
receiv
treatment
latent
tb
may
undergo
renal
transplant
complet
defin
cours
afterward
special
attent
potenti
drug
interact
toxic
karuthu
blumberg
diagnosi
tb
renal
transplant
often
requir
biopsi
infect
site
stain
acid
fast
bacilli
cultur
sensit
test
treatment
activ
diseas
transplant
requir
multipl
drug
follow
american
thorac
societi
center
diseas
control
infecti
diseas
societi
america
guidelin
mmwr
special
attent
drug
toxic
interact
immunosuppress
agent
requir
rifampin
particular
decreas
cyclosporin
level
increas
risk
reject
formerli
pneumocysti
carinii
pcp
protozoa
pathogen
current
consid
fungu
base
nucleic
acid
biochem
analysi
present
pneumonia
interstiti
infiltr
chest
xray
within
first
year
transplant
receiv
prophylaxi
mortal
may
high
nonproduct
cough
short
breath
rapid
progress
hypoxia
classic
present
diagnosi
base
silver
stain
deep
respiratori
specimen
induc
sputum
bronchoalveolar
lavag
transbronchi
biopsi
martin
fishman
treatment
choic
high
dose
trimethoprimsulfamethoxazol
day
corticosteroid
hypox
patient
partial
pressur
oxygen
mmhg
room
air
taper
day
atovaquon
clindamycin
plu
pyrimethamin
altern
agent
martin
fishman
trimethoprimsulfamethoxazol
prophylaxi
month
transplant
highli
effect
prevent
infect
administ
renal
transplant
patient
toler
frequent
use
altern
prophylaxi
allerg
patient
includ
dapson
phosphat
dehydrogenas
level
normal
atovaquon
infect
remain
import
concern
patient
undergo
kidney
transplant
attent
pretranspl
screen
potenti
organ
donor
recipi
essenti
optim
transplant
outcom
advanc
manag
transplantrel
infect
includ
increas
use
rapid
molecular
diagnost
test
well
improv
approach
prophylaxi
treatment
ongo
challeng
includ
need
prolong
immunosuppress
prevent
organ
reject
drugdrug
interact
manag
resist
emerg
pathogen
continu
awar
risk
time
present
infect
posttranspl
strategi
reduc
impact
contribut
progress
field
kidney
transplant
